Ann Dermatol.  2010 Feb;22(1):48-50. 10.5021/ad.2010.22.1.48.

A Case of p-ANCA-Positive Propylthiouracil-Induced Pyoderma Gangrenosum

• Seo JW
• Son HH
• Choi JH
• Lee SK

• KMID: 2172036
• DOI: http://doi.org/10.5021/ad.2010.22.1.48

Abstract

Propylthiouracil is a common medication used in patients with hyperthyroidism; it can cause perinuclear antineutrophil cytoplasmic antibodies (p-ANCA) in some patients with Graves' disease. This antibody has been associated with various forms of vasculitis and neutrophilic dermatosis. Herein, we report a patient who presented with cutaneous manifestations of pyoderma gangrenosum with simultaneous development of p-ANCAs during PTU therapy for Graves' disease.

Keyword

p-ANCA; Propylthiouracil; Pyoderma gangrenosum

MeSH Terms

Antibodies, Antineutrophil Cytoplasmic
Graves Disease
Humans
Neutrophils
Propylthiouracil
Pyoderma
Pyoderma Gangrenosum
Skin Diseases
Vasculitis
Antibodies, Antineutrophil Cytoplasmic
Propylthiouracil

Figure

• 

  Fig. 1 (A) Initial presentation, 20×10 cm solitary ulcer on the right flank had a violaceous border. (B) Six months after discontinuation of PTU, marked healing of the wound was observed.

• 

  Fig. 2 (A) There are dense inflammatory infiltrates throughout the dermis and subcutis (H&E, ×20). (B) Perivascular mixed cell infiltrates with some vascular damage in the papillary dermis (H&E, ×400). (C) Dense neutrophilic and eosinophilic infiltrates with leukocytoclasia and collagen degeneration in the reticular dermis (H&E, ×400).

Reference

1. Darben T, Savige J, Prentice R, Paspaliaris B, Chick J. Pyoderma gangrenosum with secondary pyarthrosis following propylthiouracil. Australas J Dermatol. 1999. 40:144–146.

2. Miller RM, Darben TA, Nedwich J, Savige J. Propylthiouracil-induced antineutrophil cytoplasmic antibodies in a patient with Graves' disease and a neutrophilic dermatosis. Br J Dermatol. 1999. 141:943–944.

3. Hong SB, Lee MH. A case of propylthiouracil-induced pyoderma gangrenosum associated with antineutrophil cytoplasmic antibody. Dermatology. 2004. 208:339–341.

4. Gungor K, Gonen S, Kisakol G, Dikbas O, Kaya A. ANCA positive propylthiouracil induced pyoderma gangrenosum. J Endocrinol Invest. 2006. 29:575–576.

5. Jacobs EM, Hartkamp A, Kaasjager HA. PTU-associated cutaneous vasculitis with ANCA anti-MPO and anti-PR3 antibodies. Neth J Med. 2003. 61:296–299.

6. Sato H, Hattori M, Fujieda M, Sugihara S, Inomata H, Hoshi M, et al. High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil. J Clin Endocrinol Metab. 2000. 85:4270–4273.

7. Kitahara T, Hiromura K, Maezawa A, Ono K, Narabara N, Yano S, et al. Case of propylthiouracil-induced vasculitis associated with anti-neutrophil cytoplasmic antibody (ANCA); review of literature. Clin Nephrol. 1997. 47:336–340.

8. Miller RM, Savige J, Nassis L, Cominos BI. Antineutrophil cytoplasmic antibody (ANCA)-positive cutaneous leucocytoclastic vasculitis associated with antithyroid therapy in Graves' disease. Australas J Dermatol. 1998. 39:96–99.

9. Wang LH, Tsai MJ, Tsai WY, Lee JS, Chiang BL. Propylthiouracil-induced antineutrophil cytoplasm antibody-positive anaphylactoid purpura-like vasculitis--a case report. J Formos Med Assoc. 2000. 99:642–645.

10. Sheen YS, Chu CY, Yu HS. Antineutrophil cytoplasmic antibody-positive cutaneous leukocytoclastic vasculitis associated with propylthiouracil therapy. Arch Dermatol. 2006. 142:879–880.